Abstract
BackgroundFrom 2017 to 2022 the oncology community has seen a significant increase in the number of cell therapy clinical trials in both hematologic malignancies and solid tumors. With breakthrough designations,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
